Oppenheimer Maintains Outperform on TransMedics Gr, Raises Price Target to $125
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on TransMedics Group (TMDX) and raises the price target from $105 to $125.
May 01, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Suraj Kalia maintains an Outperform rating on TransMedics Group and raises the price target from $105 to $125.
The increase in price target by a reputable analyst suggests a strong bullish outlook on TransMedics Group, likely leading to positive investor sentiment and potential short-term price appreciation.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100